Predict your next investment

Corporation
HEALTHCARE | Pharmaceuticals / Drugs
gsk.com

See what CB Insights has to offer

Investments

49

Portfolio Exits

31

Funds

1

Partners & Customers

10

Service Providers

2

About GlaxoSmithKline

GlaxoSmithKline (NYSE: GSK) develops and markets pharmaceuticals, vaccines, over-the-counter medicines, and health care products.

GlaxoSmithKline Headquarter Location

980 Great West Road Brentford

Middlesex, England, TW8 9GS,

United Kingdom

+44 (0)20 8047 5000

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing GlaxoSmithKline

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Find GlaxoSmithKline in 3 Expert Collections, including Diabetes.

D

Diabetes

1,750 items

M

Medical Devices

412 items

https://www.advamed.org/membership-join/membership-directory/ - excludes those without working websites.

B

Biopharma Tech

260 items

GlaxoSmithKline Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

GlaxoSmithKline Rank

Latest GlaxoSmithKline News

Fixed-dose albuterol-budesonide rescue inhaler cuts severe asthma attack risk: MANDALA

May 15, 2022

Source: Papi A, et al. The New England Journal of Medicine and JAMA Discussion on the Edge: Reports of Recently Published Pulmonary Research. Disclosures: Chipps reports consulting for AstraZeneca, Boehringer Ingelheim, Genentech, GlaxoSmithKline, Novartis, Regeneron and Sanofi. Papi reports receiving grants and personal fees from AstraZeneca, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, Menarini and Sanofi/Regeneron; personal fees from Edmond Pharma, Mundipharma, Novartis, Roche and Zambon; grants from Fondazione Maugeri and Fondazione Chiesi; and advising for Bond Avillion 2 Development LP. ADD TOPIC TO EMAIL ALERTS Receive an email when new articles are posted on Please provide your email address to receive an email when new articles are posted on . Subscribe ADDED TO EMAIL ALERTS Back to Healio We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com . Back to Healio SAN FRANCISCO — In patients with uncontrolled moderate to severe asthma, a fixed-dose combination of albuterol and budesonide used as an as-needed rescue medication lowered risk for severe asthma exacerbations compared with albuterol alone. “MANDALA met its primary endpoint: Albuterol-budesonide significantly reduced exacerbation risk vs. albuterol,” Alberto Papi, MD, professor of respiratory medicine at University of Ferrara Medical School in Italy, said during a presentation of the findings at the American Thoracic Society International Conference. Results were simultaneously published in The New England Journal of Medicine. Source: Adobe Stock. In a preplanned efficacy analysis, the primary endpoint of time to first severe asthma exacerbation was 27% lower among patients assigned a fixed-dose combination of albuterol 180 µg and budesonide 160 µg compared with albuterol 180 µg alone (HR = 0.73; 95% CI, 0.61-0.88; P < .001) and 17% lower with a lower-dose combination of albuterol 180 µg and budesonide 80 µg (HR = 0.83; 95% CI, 0.7-0.99; P = .041). In an intention-to-treat analysis, risk was reduced by 26% with the higher-dose combination (HR = 0.74; 95% CI, 0.62-0.89; P = .001) and 16% with the lower-dose combination (HR = 0.84; 95% CI, 0.71-1; P = .052), Papi said during the presentation. The study treatment, PT027, is a potential first-in class inhaled, fixed-dose combination rescue medication containing the short-acting beta 2 agonist albuterol and the inhaled corticosteroid budesonide in the U.S. It is being developed by AstraZeneca and Avillion, according to a company press release. Bradley Chipps The fixed-dose combination rescue inhaler was developed to provide rapid relief of asthma symptoms and simultaneously treat the variability of underlying inflammation when needed most, according to Papi. “Albuterol by itself, although it works initially with good bronchodilatation, does not affect the inflammatory component of asthma and as a result does not prevent exacerbations. We know one-third to 45% of patients with mild asthma exacerbate every year. We need to intervene in the ‘window of opportunity,’ which is when asthma control lessens when people become more symptomatic to prevent their progression to an exacerbation,” Bradley E. Chipps, MD, past president of the American College of Allergy, Asthma and Immunology and medical director of the Capital Allergy & Respiratory Disease Center in Sacramento, California, told Healio. The take-home message of this trial is: “You can keep your patients from having to take oral corticosteroids. No matter what you think your patients do, many don’t take their medications; they view asthma as an episodic disease. This [fixed-dose combination rescue inhaler] helps to stop episodic increases in symptoms prior to progressing to an exacerbation,” Chipps said. The phase 3, double-blind, randomized, event-driven trial enrolled symptomatic patients aged 4 years and older with moderate to severe asthma and at least one severe exacerbation in the prior year. The mean age was about 49 years, two-thirds were female and 81% were white. A total of 3,132 patients were randomly assigned to the higher-dose group, lower-dose group or albuterol only; of those, only 183 were aged 4 years to younger than 18 years. The study medication was administered via pressurized metered-dose inhaler in two actuations. All patients were receiving maintenance inhaled corticosteroids alone or combined with other controller medications. The fixed-dose combination also reduced mean annualized total systemic corticosteroid exposure and the annualized severe exacerbation rate, according to the NEJM publication. Researchers reported numerically higher odds of improvement in symptom control and quality of life with the fixed-dose combination. The incidence of any adverse event was similar across the three groups, at 46.2% in the higher-dose combination group, 47.1% in the lower-dose combination group and 46.4% in the albuterol-only group. Serious adverse events occurred in 5.2%, 3.8% and 4.5%, respectively. Adverse events were consistent with the known safety profiles of the individual components; the most common adverse events were nasopharyngitis, headache and upper respiratory tract infection. “Given the efficacy of adding budesonide to albuterol as a rescue medication and the duration of the treatment, we believe that this is going to be potentially a change in the paradigm of the use of rescue medication,” Papi said. Three phase 3 studies evaluating albuterol-budesonide fixed-dose combination as pressurized meter-dose inhaler in patients with asthma are now completed: TYREE , MANDALA and DENALI. DENALI will be presented at a later date during the ATS International Conference; this article will be updated. References:

GlaxoSmithKline Investments

49 Investments

GlaxoSmithKline has made 49 investments. Their latest investment was in LifeMine Therapeutics as part of their Series C on March 3, 2022.

CBI Logo

GlaxoSmithKline Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

3/23/2022

Series C

LifeMine Therapeutics

$175M

Yes

12

1/18/2022

Corporate Minority - P2P

23andMe

$51M

No

1

7/20/2020

Series G - II

CureVac

$297M

Yes

8

4/6/2020

Corporate Minority - P2P

Subscribe to see more

$99M

Subscribe to see more

10

4/1/2019

Series B

Subscribe to see more

$99M

Subscribe to see more

10

Date

3/23/2022

1/18/2022

7/20/2020

4/6/2020

4/1/2019

Round

Series C

Corporate Minority - P2P

Series G - II

Corporate Minority - P2P

Series B

Company

LifeMine Therapeutics

23andMe

CureVac

Subscribe to see more

Subscribe to see more

Amount

$175M

$51M

$297M

$99M

$99M

New?

Yes

No

Yes

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

12

1

8

10

10

GlaxoSmithKline Portfolio Exits

31 Portfolio Exits

GlaxoSmithKline has 31 portfolio exits. Their latest portfolio exit was 23andMe on June 17, 2021.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

6/17/2021

Reverse Merger

$99M

13

6/15/2021

Divestiture

GlaxoSmithKline - Baldriparan, Formigran, Spalt, and Kamol Brands

$99M

2

2/11/2021

Divestiture

$99M

6

8/14/2020

IPO

Subscribe to see more

$99M

Subscribe to see more

10

3/9/2020

Divestiture

Subscribe to see more

Subscribe to see more

10

Date

6/17/2021

6/15/2021

2/11/2021

8/14/2020

3/9/2020

Exit

Reverse Merger

Divestiture

Divestiture

IPO

Divestiture

Companies

GlaxoSmithKline - Baldriparan, Formigran, Spalt, and Kamol Brands

Subscribe to see more

Subscribe to see more

Valuation

$99M

$99M

$99M

$99M

Acquirer

Subscribe to see more

Subscribe to see more

Sources

13

2

6

10

10

GlaxoSmithKline Acquisitions

20 Acquisitions

GlaxoSmithKline acquired 20 companies. Their latest acquisition was Sierra Oncology on April 13, 2022.

Date

Investment Stage

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Total Funding

Note

Sources

4/13/2022

Series D

$99M

$79.83M

Acq - Pending

6

9/11/2019

Series A

$99M

$10M

Acquired

6

12/19/2018

Other

$99M

Corporate Majority

2

12/3/2018

Series B

Subscribe to see more

$99M

$99M

Subscribe to see more

10

3/27/2018

Other

Subscribe to see more

$99M

$99M

Subscribe to see more

10

Date

4/13/2022

9/11/2019

12/19/2018

12/3/2018

3/27/2018

Investment Stage

Series D

Series A

Other

Series B

Other

Companies

Subscribe to see more

Subscribe to see more

Valuation

$99M

$99M

$99M

$99M

$99M

Total Funding

$79.83M

$10M

$99M

$99M

Note

Acq - Pending

Acquired

Corporate Majority

Subscribe to see more

Subscribe to see more

Sources

6

6

2

10

10

GlaxoSmithKline Fund History

1 Fund History

GlaxoSmithKline has 1 fund, including Action Potential Venture Capital Ltd..

Closing Date

Fund

Fund Type

Status

Amount

Sources

8/8/2013

Action Potential Venture Capital Ltd.

Multi-Stage Venture Capital

Closed

$50M

1

Closing Date

8/8/2013

Fund

Action Potential Venture Capital Ltd.

Fund Type

Multi-Stage Venture Capital

Status

Closed

Amount

$50M

Sources

1

GlaxoSmithKline Partners & Customers

10 Partners and customers

GlaxoSmithKline has 10 strategic partners and customers. GlaxoSmithKline recently partnered with Vir Biotechnology on April 4, 2022.

Date

Type

Business Partner

Country

News Snippet

Sources

4/6/2022

Partner

United States

Sarah Silbiger/Getty Images. Published: Apr 06, 2022By Hayley Shasteen. FDA Fully Revokes Authorization of GSK and Vir's Sotrovimab for COVID-19.

GSK and Vir Biotechnology both maintain that the treatment is effective against BA .2 despite disagreement from the scientific community .

1

4/5/2022

Partner

United States

PathAI and GlaxoSmithKline Sign Multi-Year Agreement to Accelerate Research and Drug Development

`` Our partnership will combine GlaxoSmithKline and PathAI 's AI and platform engineering teams to scale algorithm development and enable the discovery of new insights that can be rapidly integrated into clinical trials , '' said Andrew Beck , CEO and Co-founder of PathAI .

2

4/5/2022

Vendor

United States

AI-powered pathology startup PathAI teams up with GSK for drug discovery

`` Our partnership will combine GSK and PathAI 's AI and platform engineering teams to scale algorithm development and enable the discovery of new insights that can be rapidly integrated into clinical trials , '' PathAI CEO and cofounder Andrew Beck said in a statement .

2

3/25/2022

Partner

United States

Subscribe to see more

Subscribe to see more

10

3/23/2022

Licensor

United States

Subscribe to see more

Subscribe to see more

10

Date

4/6/2022

4/5/2022

4/5/2022

3/25/2022

3/23/2022

Type

Partner

Partner

Vendor

Partner

Licensor

Business Partner

Country

United States

United States

United States

United States

United States

News Snippet

Sarah Silbiger/Getty Images. Published: Apr 06, 2022By Hayley Shasteen. FDA Fully Revokes Authorization of GSK and Vir's Sotrovimab for COVID-19.

GSK and Vir Biotechnology both maintain that the treatment is effective against BA .2 despite disagreement from the scientific community .

PathAI and GlaxoSmithKline Sign Multi-Year Agreement to Accelerate Research and Drug Development

`` Our partnership will combine GlaxoSmithKline and PathAI 's AI and platform engineering teams to scale algorithm development and enable the discovery of new insights that can be rapidly integrated into clinical trials , '' said Andrew Beck , CEO and Co-founder of PathAI .

AI-powered pathology startup PathAI teams up with GSK for drug discovery

`` Our partnership will combine GSK and PathAI 's AI and platform engineering teams to scale algorithm development and enable the discovery of new insights that can be rapidly integrated into clinical trials , '' PathAI CEO and cofounder Andrew Beck said in a statement .

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Sources

1

2

2

10

10

GlaxoSmithKline Service Providers

2 Service Providers

GlaxoSmithKline has 2 service provider relationships

Service Provider

Associated Rounds

Provider Type

Service Type

Acq - P2P

Investment Bank

Financial Advisor

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Service Provider

Subscribe to see more

Associated Rounds

Acq - P2P

Subscribe to see more

Provider Type

Investment Bank

Subscribe to see more

Service Type

Financial Advisor

Subscribe to see more

Partnership data by VentureSource

GlaxoSmithKline Team

91 Team Members

GlaxoSmithKline has 91 team members, including current President, Hal V Barron.

Name

Work History

Title

Status

Hal V Barron

President

Current

Simon Dingemans

Chief Financial Officer

Current

Manjeet Aujla

Chief Information Officer, Senior Vice President

Current

Vincent Brichard

Senior Vice President

Current

Robin Carr,

Senior Vice President

Current

Name

Hal V Barron

Simon Dingemans

Manjeet Aujla

Vincent Brichard

Robin Carr,

Work History

Title

President

Chief Financial Officer

Chief Information Officer, Senior Vice President

Senior Vice President

Senior Vice President

Status

Current

Current

Current

Current

Current

You May Also Like

J
Janssen Pharmaceuticals

Janssen Pharmaceuticals is a pharmaceutical company that provides medicines for an array of health concerns in several therapeutic areas. These include: attention deficit hyperactivity disorder (ADHD), general medicine (acid reflux disease, infectious diseases), mental health (bipolar I disorder, schizophrenia), neurologics (Alzheimer's disease, epilepsy, migraine prevention and treatment), pain management, and women's health.

M
Mundipharma International

The Mundipharma network of independent associated companies consists of privately owned companies and joint ventures covering the world's pharmaceutical markets. These companies are committed to bringing to patients the benefits of pioneering treatment options in the core therapy areas of oncology, pain, respiratory and inflammatory conditions. They are also committed to independent thinking and ground breaking solutions. Through innovation, design and acquisition, the Mundipharma network of independent associated companies delivers cutting‐edge treatments to meet the most pressing needs of healthcare professionals and patients.

G
Grunenthal Group

The Grunenthal Group is a science-based pharmaceutical company that seeks to bring treatments and technologies to patients worldwide. The company focuses on pain management and related diseases.

E
Eli Lilly and Company

Eli Lilly and Company (NYSE: LLY) is a global healthcare company that unites caring with discovery to make life better for people around the world. Lilly works to discover and bring medicines to those who need them, improve the understanding and management of disease, and give back to communities through philanthropy and volunteerism.

Roche Holding Logo
Roche Holding

Roche Holding is the holding company of F. Hoffmann-La Roche (Roche), a Swiss multinational research-focused healthcare company that discovers, develops and provides diagnostic and therapeutic products and services. Roche operates worldwide under two divisions: Pharmaceuticals and Diagnostics.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.